Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial - The Lancet Neurology
1 view
Skip to first unread message
Carla Gouveia
Sep 19, 2025, 1:09:12 AM9/19/25
to
Reply all
Reply to author
Forward
0 new messages